BioCentury | Mar 23, 2018
Financial News

Neuromuscular play NMD raises EUR38M in series A

...to four years. NMD Pharma ApS, Aarhus, Denmark Allison Johnson INKEF Capital Lundbeckfond Emerge NMD Pharma ApS Novo Seeds Roche Venture Fund Chloride voltage-gated channel 1 (CLCN1) (CLC1)...
BioCentury | Mar 22, 2018
Financial News

NMD raises €38M series A

...NMD to bring both candidates to Phase II within three to four years. Allison Johnson NMD Pharma ApS Chloride voltage-gated channel 1 (CLCN1) (CLC1)...
BioCentury | Mar 22, 2018
Finance

NMD treats A to Z

The broad applicability of NMD Pharma ApS’s approach to treating neuromuscular conditions persuaded INKEF Capital to lead the company’s tranched €38 million ($46.6 million) series A round. Fellow new investor Roche Venture Fund and existing...
Items per page:
1 - 3 of 3